Biofrontera Inc. Announces Voting Results from 2022 Annual Meeting of Stockholders
2022年12月16日 - 10:30PM
Biofrontera
Inc. (Nasdaq: BFRI),
a biopharmaceutical company specializing in the commercialization
of dermatological products, today announced the final voting
results from its 2022 Annual Meeting of Stockholders held on
December 12, 2022.
- Stockholders re-elected board
nominee Loretta M. Wedge to the Biofrontera Inc. Board of Directors
as Class I director to serve until the 2025 Annual Meeting of
Stockholders.
- Stockholders approved an amendment
to the Biofrontera Inc. 2021 Omnibus Incentive Plan to increase the
number of shares authorized for issuance under the plan by
2,589,800 shares.
- Stockholders ratified the
appointment of Grant Thornton LLP as the Company’s independent
registered public accounting firm for the 2022 fiscal year.
The final vote tally are reported in a Current
Report on Form 8-K filed with the Securities and Exchange
Commission.
About
Biofrontera Inc.
Biofrontera Inc. is a U.S.-based
biopharmaceutical company commercializing a portfolio of
pharmaceutical products for the treatment of dermatological
conditions with a focus on photodynamic therapy (PDT) and topical
antibiotics. The Company’s licensed products are used for the
treatment of actinic keratoses, which are pre-cancerous skin
lesions, as well as impetigo, a bacterial skin infection. For more
information, visit www.biofrontera-us.com.
Forward-Looking Statements
Certain statements in this press release may
constitute "forward-looking statements" within the meaning of the
United States Private Securities Litigation Reform Act of 1995, as
amended to date. We have based any forward-looking statements on
our current expectations and projections about future events,
nevertheless, actual results or events could differ materially from
the plans, intentions and expectations disclosed in, or implied by,
the forward-looking statements we make. These risks and
uncertainties, many of which are beyond our control, including, but
not limited to, the impact of extraordinary external events, such
as the current COVID-19 pandemic; any changes in the Company’s
relationship with its licensors; the ability of the Company’s
licensors to fulfill their obligations to the Company in a timely
manner; the Company’s ability to achieve and sustain profitability;
whether the current global disruptions in supply chains will impact
the Company’s ability to obtain and distribute its licensed
products; changes in the practices of healthcare providers,
including any changes to the coverage, reimbursement and pricing
for procedures using the Company’s licensed products; the
uncertainties inherent in the initiation and conduct of clinical
trials; availability and timing of data from clinical trials;
whether results of earlier clinical trials or trials of Ameluz® in
combination with BF-RhodoLED® in different disease indications or
product applications will be indicative of the results of ongoing
or future trials; uncertainties associated with regulatory review
of clinical trials and applications for marketing approvals;
whether the market opportunity for Ameluz® in combination with
BF-RhodoLED® is consistent with the Company’s expectations; the
Company’s ability to complete the transition to a public company;
the Company’s ability to retain and hire key personnel; the
sufficiency of cash resources and need for additional financing and
other factors that may be disclosed in the Company’s filings with
the SEC, which can be obtained on the SEC website at www.sec.gov.
Readers are cautioned not to place undue reliance on the
forward-looking statements, which speak only as of the date on
which they are made and reflect management's current estimates,
projections, expectations and beliefs. The Company does not plan to
update any such forward-looking statements and expressly disclaims
any duty to update the information contained in this press release
except as required by law.
Contacts:Biofrontera
Inc. Investor Relationsir@bfinc.com
Biofrontera (NASDAQ:BFRIW)
過去 株価チャート
から 8 2024 まで 9 2024
Biofrontera (NASDAQ:BFRIW)
過去 株価チャート
から 9 2023 まで 9 2024